MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$18,591K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation
Non-cash interest expense - roya...
Others
Negative Cash Flow Breakdown
Net loss
Purchase of marketable securitie...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-21,870
-15,767
-12,714
-29,001
Non-cash interest expense - royalty agreement
2,308
2,039
1,739
4,079
Non-cash interest expense - convertible notes
-
-
0
0
Change in fair value of derivative liabilities - royalty agreement
114
116
119
82
Change in fair value of derivative liabilities - contingent value right agreement
-
-
-
238
Change in fair value of derivative liabilities - contingent value right liability
0
-202
218
-
Change in fair value of convertible notes payable
-
-
0
0
Stock-based compensation
5,155
3,376
2,084
1,790
Accretion on marketable securities
320
15
-
-
Non-cash lease operating expense
45
44
62
-
Costs to issue convertible notes
-
-
0
0
Accounts receivable
-
-
-29
0
German research and development tax credit receivable
-
-
-2,105
-
Prepaid expenses and other current assets
1,065
357
-222
-182
Accounts payable
1,351
851
1,156
-1,136
Accrued expenses and other current liabilities
1,486
-900
292
801
Payments on operating lease liabilities
-49
-49
-
-
Net cash used in operating activities
-12,845
-10,864
-4,926
-7,878
Purchase of marketable securities
15,032
55,440
-
-
Maturities of marketable securities
8,000
-
-
-
Cash acquired from reverse merger transaction
-
-
0
-
Net cash used in investing activities
-7,032
-55,440
-
-
Payment of transaction costs in connection with reverse merger
0
0
0
0
Proceeds from pipe financing
-
-
0
-
Payments of transaction costs associated with pipe financing
-
-
0
-
Proceeds from issuance of common stock in connection with equity financing
0
230,000
-
-
Proceeds from issuance of convertible notes
-
-
0
0
Payment of financing cost in connection with equity financing
0
14,247
-
-
Payment of transaction costs to issue convertible notes
-
-
0
0
Payment of contingent value right liability
0
1,978
-
-
Proceeds from exercise of stock options
1,280
956
105
242
Deferred equity issuance costs
-
-
154
-
Net cash provided by (used in) financing activities
1,280
214,731
-49
242
Effect of exchange rate change on cash and cash equivalents
6
-15
-610
770
Net increase (decrease) in cash and cash equivalents
-18,591
148,412
-5,585
-6,866
Cash and cash equivalents at beginning of period
206,394
57,982
63,567
83,602
Cash and cash equivalents at end of period
187,803
206,394
57,982
63,567
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$1,280K
(207.69%↑ Y/Y)
Net cash provided by
(used in) financing...
$1,280K
(250.06%↑ Y/Y)
Effect of exchange rate
change on cash and cash...
$6K
(105.26%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$18,591K
(-41.17%↓ Y/Y)
Canceled cashflow
$1,286K
Stock-based compensation
$5,155K
(104.00%↑ Y/Y)
Non-cash interest
expense - royalty...
$2,308K
(-10.16%↓ Y/Y)
Accrued expenses and
other current...
$1,486K
(162.10%↑ Y/Y)
Accounts payable
$1,351K
(8.95%↑ Y/Y)
Change in fair value of
derivative liabilities -...
$114K
(-40.93%↓ Y/Y)
Non-cash lease operating
expense
$45K
Maturities of marketable
securities
$8,000K
Net cash used in
operating activities
-$12,845K
(-5.27%↓ Y/Y)
Net cash used in
investing activities
-$7,032K
Canceled cashflow
$10,459K
Canceled cashflow
$8,000K
Net loss
-$21,870K
(-23.87%↓ Y/Y)
Purchase of marketable
securities
$15,032K
Prepaid expenses and
other current assets
$1,065K
(210.94%↑ Y/Y)
Accretion on marketable
securities
$320K
Payments on operating
lease liabilities
-$49K
Buy us a coffee
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)